Altimmune, Inc.

XNASHealth care

Last traded price · USD

$2.14

+0.94%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:57 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $2.12
Volume: 315
Day's high: —
Day's low: —

In brief

Altimmune, Inc. is a health care company listed on Nasdaq, valued at about $416M.
Its shares closed at $2.12 on 4 Nov 2026, down 43.6% over the past year.
From India you can buy ALT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Altimmune, Inc. (ALT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ALT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ALT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −20.6% (SPY −1.6%, XLV +13.5%). 3 months: −30.0% (SPY −0.4%, XLV +15.5%). 1 year: −43.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALT, SPY and XLV · as of 4 Nov 2026
6.5% above its 52-week low
Closed at $2.12 on 4 Nov 2026: 67.1% below the 52-week high of $6.44 (23 Jan 2026) and 6.5% above the low of $1.99 (30 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
10.4 days to cover short interest
42.2M shares were sold short at the 15 Oct 2026 settlement, 21.7% of the 194.5M shares outstanding; covering them would take 10.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $2.12 was 23.2% below its 50-day average ($2.76) and 34.8% below its 200-day average ($3.25). It has closed below the 200-day for 175 sessions, since 26 Feb 2026. The 50-day average crossed below the 200-day on 6 Apr 2026, 148 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−20.6%

6 months−35.0%

1 year−43.6%

5 years−80.7%

Newswire

About

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Website

Notable moves

June 26, 2025
−53.18%
December 6, 2023
+33.08%
March 21, 2023
−54.67%

Altimmune, Inc.

XNASHealth care

Last traded price · USD

$2.14

+0.94%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:57 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $2.12
Volume: 315
Day's high: —
Day's low: —

In brief

Altimmune, Inc. is a health care company listed on Nasdaq, valued at about $416M.
Its shares closed at $2.12 on 4 Nov 2026, down 43.6% over the past year.
From India you can buy ALT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Altimmune, Inc. (ALT) shares from India?

Do I need the price of a whole ALT share to invest?

How much can I invest in US stocks in a year?

Can I trade ALT options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −20.6% (SPY −1.6%, XLV +13.5%). 3 months: −30.0% (SPY −0.4%, XLV +15.5%). 1 year: −43.6% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALT, SPY and XLV · as of 4 Nov 2026
6.5% above its 52-week low
Closed at $2.12 on 4 Nov 2026: 67.1% below the 52-week high of $6.44 (23 Jan 2026) and 6.5% above the low of $1.99 (30 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
10.4 days to cover short interest
42.2M shares were sold short at the 15 Oct 2026 settlement, 21.7% of the 194.5M shares outstanding; covering them would take 10.4 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $2.12 was 23.2% below its 50-day average ($2.76) and 34.8% below its 200-day average ($3.25). It has closed below the 200-day for 175 sessions, since 26 Feb 2026. The 50-day average crossed below the 200-day on 6 Apr 2026, 148 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−20.6%

6 months−35.0%

1 year−43.6%

5 years−80.7%

Newswire

About

Website

Notable moves

June 26, 2025
−53.18%
December 6, 2023
+33.08%
March 21, 2023
−54.67%

Altimmune, Inc.

Altimmune, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

6.5% above its 52-week low

10.4 days to cover short interest

Below its 50- and 200-day averages

Altimmune, Inc.

Altimmune, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

6.5% above its 52-week low

10.4 days to cover short interest

Below its 50- and 200-day averages